Our goal is to revolutionize cancer therapy on a global basis by developing TCR therapies with the potential to treat a wide range of cancer types and patients.

Our T-cell therapies have advantages over other immune therapies and cancer therapies.

Our T-cell therapies are capable of recognizing peptide fragments from both proteins present inside the cell and expressed on the outside of the cell. We can therefore target a large number of proteins.

More targets, inside the cancer cell and out, means more options for targeting these cancers.

Our T-cell therapies are all subjected to a meticulous pre-screening package which aims to minimize any chance that our T-cell therapies might bind to peptides other than the intended target cancer peptide.

Better specificity, we believe, improves the safety profile of our T-cell therapies.

Our T-cell therapies can target both solid cancers, such as synovial sarcoma and ovarian cancers and hematologic cancers. Our T-cell therapies have general applicability to a wide range of cancer types, many of which currently have low patient survival rates.

  • NY-ESO 1Sarcoma, Melanoma, Myeloma, Lung, Ovarian, Esophagogastric, Breast, Others
  • MAGE-A10Head & Neck, Bladder, Lung, Breast, Ovarian, Melanoma, Cervical, Uterine, Others
  • AFPHepatocellular carcinoma
  • 12 Other Targets in ResearchMultiple targets on most solid and hematologic cancers

We enhance the body's natural systems by affinity engineering naturally occurring T-cell receptors to recognize and bind to specific cancer peptides.

In addition to our clinical pipeline, we have a large pipeline of identified and validated targets against which we can direct new T-cell therapies.

We believe that our T-cell therapies may one day be capable of treating patients who have limited, if any, treatments available.